Singular Genomics Systems adds Dr. Elaine Mardis to its Board of Directors

– USA, CA –  Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing and multi-omics technologies to empower researchers and clinicians, today announced the addition of Dr. Elaine Mardis (Ph.D.) to its Board of Directors.

“We are thrilled to have Elaine join the Board of Directors. She brings the rare combination of world-class scientific, industry and governance talents to the role. As a preeminent researcher and leader in cancer genomics – whose work in DNA sequencing has led to significant advances in the understanding of genetic mutations and how they relate to cancer – Elaine will provide invaluable insights to our team. Singular Genomics is a science and technology company first. In addition to a strong science and technical background, Elaine’s unique position as a leader in precision medicine who is driving clinical applications of genomics lends itself to our longer-term focus in delivering superior clinical sequencing solutions,” said Chairman and CEO, Drew Spaventa.

About Dr. Elaine R. Mardis

Dr. Mardis is a pioneering researcher internationally recognized in cancer genomics with a focus on the application of genomic technologies to improve the understanding of human disease and the precision of medical diagnosis, prognosis, and treatment.

Since 2016, Dr. Mardis has served as Co-Executive Director of the Institute of Genomic Medicine at Nationwide Children’s Hospital and holds the Steve and Cindy Rasmussen Endowed Chair in Genomic Medicine. She is also a Professor of Pediatrics at The Ohio State University College of Medicine. Additionally, Dr. Mardis serves on the Supervisory Board, Science and Technology Committee, and the Compensation and Human Resources Committee at Qiagen. She is currently Deputy Editor for the peer-reviewed journal Disease Models and Mechanisms, Co-Editor-in-Chief of Cancer Research Communications, and Editor-in-Chief of Molecular Case Studies. Previously, Dr. Mardis was a member of the faculty of Washington University School of Medicine for 22 years. Dr. Mardis received her Bachelor of Science degree in zoology and her Ph.D. in chemistry and biochemistry, both from the University of Oklahoma. She has authored more than 380 articles in peer-reviewed journals, has contributed chapters for several medical textbooks, and is an elected member of the U.S. National Academy of Medicine.

“Following the recent launch of the G4 sequencing platform, Singular is well-positioned to become a leader in the next-generation sequencing space, with impressive technology and a strong team committed to improving human health. I look forward to working with Drew, the leadership team, and the Board to support the continued evolution of Singular’s sequencing technologies which will help drive advances in science and medicine,” said Dr. Mardis.

About Singular Genomics Systems, Inc.

Singular Genomics is a life science technology company that is leveraging novel, next-generation sequencing and multi-omics technologies to build products that empower researchers and clinicians. Our mission is to accelerate genomics for the advancement of science and medicine. Our Singular Sequencing Engine is the foundational platform technology that forms the basis of our products in development as well as our core product tenets: accuracy, speed, flexibility, and power. We are currently developing two integrated solutions that are purpose-built to target applications in which these core product tenets matter most. Our first integrated solution, the G4 sequencing platform, is targeted at the NGS market. Our second integrated solution in development, the PX, combines single-cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument to offer a versatile multi-omics solution. The G4 and PX sequencing platforms are both comprised of an instrument and an associated menu of consumable kits.

For more information: https://singulargenomics.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team